Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA).

Trial Profile

Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA).

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2011

At a glance

  • Drugs Eldelumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Medarex
  • Most Recent Events

    • 06 Dec 2011 Results published in the Arthritis and Rheumatism.
    • 13 Mar 2010 Bristol-Myers Squibb added as trial sponsor, trial affiliate and lead trial centre as reported by ClinicalTrials.gov.
    • 23 Nov 2009 Actual initiation date changed from 12 May 2008 to Feb 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top